Info

🌱 來自: Metastatic Colon Cancer

ramucirumab

• Mechanism: Binds to VEGFR2
• Dosing: Dosing dependent on dz; colorectal/gastric: 8 mg/kg IV every 2 wks as part of combination therapy; NSCLC 10 mg/kg every 21 d w/ docetaxel
  • mCRC: 8 mg/kg every 2 weeks in combination with fluorouracil, leucovorin (folinic acid), and irinotecan (FOLFIRI)
• PK/PD: T1/2 ∼14 d
• AEs:
  • HTN,
  • anemia,
  • diarrhea,
  • proteinuria,
  • neutropenia,
  • infusion-related rxns
  • reversible posterior leukoencephalopathy syndrome (RPLS) occurs
• DDI: No known pathways of metabolism
• Clinical pearls: Premedications required; pts w/ HTN should be controlled prior to administration & BPs monitored closely

$ 11,531 (100 mg), 48,038 (500 mg)

大腸直腸癌: Ramucirumab 併用FOLFIRI (irinotecan、葉酸及5-fluorouracil) 適用於治療正接受或接受過 bevacizumab、oxaliplatin 及 fluoropyrimidine 治療仍疾病惡化之轉移性大腸直腸癌 (mCRC)。